Literature DB >> 22246920

Pheochromocytoma and Paraganglioma: progress on all fronts.

Anne-Paule Gimenez-Roqueplo, Arthur S Tischler.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22246920     DOI： 10.1007/s12022-011-9190-7

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN： 1046-3976            Impact factor:   3.943


× No keyword cloud information.
  17 in total

1.  Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.

Authors:  M S Elston; G Y Meyer-Rochow; I Holdaway; J V Conaglen
Journal:  Horm Metab Res       Date:  2012-01-24       Impact factor: 2.936

Review 2.  Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.

Authors:  P-F Plouin; P Fitzgerald; T Rich; M Ayala-Ramirez; N D Perrier; E Baudin; C Jimenez
Journal:  Horm Metab Res       Date:  2012-02-07       Impact factor: 2.936

3.  Pheochromocytoma and paraganglioma: recent progress and new vistas for improved patient care.

Authors:  G Eisenhofer; M Schott; S Bornstein
Journal:  Horm Metab Res       Date:  2012-05-07       Impact factor: 2.936

4.  Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicate a need for caution.

Authors:  G Eisenhofer; C D Vocke; A Elkahloun; T-T Huynh; T Prodanov; J W M Lenders; H J Timmers; J N Benhammou; W M Linehan; K Pacak
Journal:  Horm Metab Res       Date:  2012-03-21       Impact factor: 2.936

Review 5.  Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.

Authors:  H J L M Timmers; D Taieb; K Pacak
Journal:  Horm Metab Res       Date:  2012-03-07       Impact factor: 2.936

6.  Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary consultation.

Authors:  K Lahlou-Laforêt; S M Consoli; X Jeunemaitre; A-P Gimenez-Roqueplo
Journal:  Horm Metab Res       Date:  2012-04-19       Impact factor: 2.936

7.  High incidence of cardiovascular complications in pheochromocytoma.

Authors:  T Zelinka; O Petrák; H Turková; R Holaj; B Strauch; M Kršek; A B Vránková; Z Musil; J Dušková; J Kubinyi; D Michalský; K Novák; J Widimský
Journal:  Horm Metab Res       Date:  2012-04-19       Impact factor: 2.936

Review 8.  Perioperative management of pheochromocytoma/paraganglioma: is there a state of the art?

Authors:  M Mannelli; H Dralle; J W M Lenders
Journal:  Horm Metab Res       Date:  2012-04-19       Impact factor: 2.936

9.  Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.

Authors:  J Spetz; J Dalmo; O Nilsson; B Wängberg; H Ahlman; E Forssell-Aronsson
Journal:  Horm Metab Res       Date:  2012-05-07       Impact factor: 2.936

10.  Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.

Authors:  A Persu; N Lannoy; D Maiter; A Mendola; P Montigny; P Oriot; W Vinck; P Garin; M Hamoir; M Vikkula
Journal:  Horm Metab Res       Date:  2012-05-07       Impact factor: 2.936
View more
  7 in total

1.  Totally laparoscopic resection of a rare duodenal tumour.

Authors:  Christopher Hadjittofi; Constantinos A Parisinos; Mostafa Somri; Ibrahim Matter
Journal:  BMJ Case Rep       Date:  2012-05-30

Review 2.  Connecting molecular pathways to hereditary cancer risk syndromes.

Authors:  Joseph R Testa; David Malkin; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

3.  Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas.

Authors:  Ozgur Mete; Arthur S Tischler; Ronald de Krijger; Anne Marie McNicol; Graeme Eisenhofer; Karel Pacak; Shereen Ezzat; Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2014-02       Impact factor: 5.534

4.  A novel mutation (P236S) in the succinate dehydrogenase subunit B gene in a Japanese patient with a posterior mediastinal paraganglioma.

Authors:  Haruhiro Sato; Sunao Shoji; Hiroshi Kajiwara; Johbu Itoh; Robert Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2013-09       Impact factor: 3.943

5.  Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.

Authors:  Clarissa A Cassol; Daniel Winer; Wei Liu; Miao Guo; Shereen Ezzat; Sylvia L Asa
Journal:  Mod Pathol       Date:  2014-01-03       Impact factor: 7.842

6.  Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.

Authors:  Anna Merlo; Cristóbal Bernardo-Castiñeira; Inés Sáenz-de-Santa-María; Ana S Pitiot; Milagros Balbín; Aurora Astudillo; Nuria Valdés; Bartolomé Scola; Raquel Del Toro; Simón Méndez-Ferrer; José I Piruat; Carlos Suarez; María-Dolores Chiara
Journal:  Oncotarget       Date:  2017-01-24

7.  Landscape of the mitochondrial Hsp90 metabolome in tumours.

Authors:  Young Chan Chae; Alessia Angelin; Sofia Lisanti; Andrew V Kossenkov; Kaye D Speicher; Huan Wang; James F Powers; Arthur S Tischler; Karel Pacak; Stephanie Fliedner; Ryan D Michalek; Edward D Karoly; Douglas C Wallace; Lucia R Languino; David W Speicher; Dario C Altieri
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.